% | $
Quotes you view appear here for quick access.


  • dogwooody dogwooody Feb 4, 2010 6:25 PM Flag

    saw this mentioned on another biotech board

    after looking at it. . .

    600 Million Shares outstanding?
    less than 1% institutional/insider ownership?

    way too early in this stock as they'll have to reverse split probably 1:15 or 1:20 to get the outstanding shares down to a manageable level.

    You guys in now may have found a company destined to be successful, but imo, if you're in right now, you won't be the shareholders who will participate in this success.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ronaldschobel Feb 4, 2010 9:15 PM Flag

      Your point is well taken. I agree w/your assessment. You certainly stirred up a few on this board. That is why I no longer buy ACTC and hold shares that will handle the split. It's a good thing I made $'s when this was at .001. The storm is on the horizon. Thanks for the post=awareness for all.

    • tinmanken Feb 4, 2010 8:28 PM Flag

      As filed with the securities and exchange commission on february 1, 2010

    • tinmanken Feb 4, 2010 8:26 PM Flag

      "Without additional capital, we may not have the resources to adequately defend or pursue this litigation."

      Enough money for the next two years? please!

    • tinmanken Feb 4, 2010 8:25 PM Flag

      Patent litigation presents an ongoing threat to our business with respect to both outcomes and costs.

      We have previously been involved in patent interference litigation, and it is possible that further litigation over patent matters with one or more competitors could arise. We could incur substantial litigation or interference costs in defending ourselves against suits brought against us or in suits in which we may assert our patents against others. If the outcome of any such litigation is unfavorable, our business could be materially adversely affected. To determine the priority of inventions, we may also have to participate in interference proceedings declared by the United States Patent and Trademark Office, which could result in substantial cost to us. Without additional capital, we may not have the resources to adequately defend or pursue this litigation.

    • tinmanken Feb 4, 2010 8:24 PM Flag

      We may not be able to commercially develop our technologies and proposed product lines, which, in turn, would significantly harm our ability to earn revenues and result in a loss of investment.

      Our ability to commercially develop our technologies will be dictated in large part by forces outside our control which cannot be predicted, including, but not limited to, general economic conditions, the success of our research and pre-clinical and field testing, the availability of collaborative partners to finance our work in pursuing applications of nuclear transfer technology and technological or other developments in the biomedical field which, due to efficiencies, technological breakthroughs or greater acceptance in the biomedical industry, may render one or more areas of commercialization more attractive, obsolete or competitively unattractive. It is possible that one or more areas of commercialization will not be pursued at all if a collaborative partner or entity willing to fund research and development cannot be located. Our decisions regarding the ultimate products and/or services we pursue could have a significant adverse affect on our ability to earn revenue if we misinterpret trends, underestimate development costs and/or pursue wrong products or services. Any of these factors either alone or in concert could materially harm our ability to earn revenues or could result in a loss of any investment in us.

    • tinmanken Feb 4, 2010 8:23 PM Flag

      Over the last twelve months we have narrowed our potential product pool to focusing on our Retinal Program as well as the applications of our I.P.S. technology, which will limit our revenue sources

    • tinmanken Feb 4, 2010 8:23 PM Flag

      We are dependent on new and unproven technologies.

      Our risks as an early stage company are compounded by our heavy dependence on emerging and sometimes unproven technologies. If these technologies do not produce satisfactory results, our business may be harmed. Additionally some of our technologies and significant potential revenue sources involve ethically sensitive and controversial issues which could become the subject of legislation or regulations that could materially restrict our operations and, therefore, harm our financial condition, operating results and prospects for bringing our investors a return on their investment.

    • tinmanken Feb 4, 2010 8:22 PM Flag

      We have limited clinical testing, regulatory, manufacturing, marketing, distribution and sales capabilities which may limit our ability to generate revenues.

      Due to the relatively early stage of our therapeutic products, regenerative medical therapies and stem cell therapy-based programs, we have not yet invested significantly in regulatory, manufacturing, marketing, distribution or product sales resources. We cannot assure you that we will be able to invest or develop any of these resources successfully or as expediently as necessary. The inability to do so may inhibit or harm our ability to generate revenues or operate profitably.

    • tinmanken Feb 4, 2010 8:22 PM Flag

      Our business is at an early stage of development and we may not develop therapeutic products that can be commercialized.

      We do not yet have any product candidates in late-stage clinical trials or in the marketplace. Our potential therapeutic products will require extensive preclinical and clinical testing prior to regulatory approval in the United States and other countries. We may not be able to obtain regulatory approvals (see REGULATORY RISKS), enter clinical trials for any of our products, or commercialize any products. Our therapeutic and product candidates may prove to have undesirable and unintended side effects or other characteristics adversely affecting their safety, efficacy or cost-effectiveness that could prevent or limit their use. Any product using any of our technology may fail to provide the intended therapeutic benefits, or achieve therapeutic benefits equal to or better than the standard of treatment at the time of testing or production. In addition, we will need to determine whether any of our potential products can be manufactured in commercial quantities or at an acceptable cost. Our efforts may not result in a product that can be or will be marketed successfully. Physicians may not prescribe our products, and patients or third party payors may not accept our products. For these reasons we may not be able to generate revenues from commercial production.

    • tinmanken Feb 4, 2010 8:22 PM Flag

      Risks Relating to the Company’s Early Stage of Development

      We may not be able to continue as a going concern.

      Our consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have a history of operating losses that are likely to continue in the future. Our auditors have included an explanatory paragraph in their Report of Independent Registered Public Accounting Firm included in our audited consolidated financial statements for the years ended December 31, 2008 and 2007 to the effect that our significant losses from operations and our dependence on equity and debt financing raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.

    • View More Messages